Cassava Sciences Invited by the NIH to Participate in Sachs 4th Annual Neuroscience Innovation Forum
April 26 2021 - 8:30AM
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage
biotechnology company focused on Alzheimer’s disease, today
announced that it has been invited to participate in the Sachs 4th
Annual Neuroscience Innovation Forum, a virtual event held on April
28-30, 2021. The National Institute on Aging of the National
Institutes of Health (NIH) has invited Cassava Sciences to showcase
its scientific program at this event.
Lindsay Burns, PhD, Senior VP Neuroscience, will
provide a pre-recorded, 10-minute overview of Cassava Sciences’
program in Alzheimer’s disease during this event. A link for this
webcast will be available on Cassava Sciences’ website on
Wednesday, April 28th starting 8:30AM Eastern time and will remain
there for approximately 90 days thereafter.
About Cassava Sciences,
Inc.Cassava Sciences’ mission is to discover and develop
innovations for chronic, neurodegenerative conditions. Over the
past 10 years, Cassava Sciences has combined state-of-the-art
technology with new insights in neurobiology to develop novel
solutions for Alzheimer’s disease. For more information, please
visit: https://www.CassavaSciences.com.
For More Information Contact:
Eric Schoen, Chief Financial
Officereschoen@CassavaSciences.com(512) 501-2450
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Sep 2023 to Sep 2024